ZA963826B - A method of treatment of mania and bipolar disorder - Google Patents

A method of treatment of mania and bipolar disorder

Info

Publication number
ZA963826B
ZA963826B ZA963826A ZA963826A ZA963826B ZA 963826 B ZA963826 B ZA 963826B ZA 963826 A ZA963826 A ZA 963826A ZA 963826 A ZA963826 A ZA 963826A ZA 963826 B ZA963826 B ZA 963826B
Authority
ZA
South Africa
Prior art keywords
treatment
mania
bipolar disorder
gabapentin
recurrent
Prior art date
Application number
ZA963826A
Other languages
English (en)
Inventor
Atul Chandra Pande
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA963826B publication Critical patent/ZA963826B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
ZA963826A 1995-05-15 1996-05-14 A method of treatment of mania and bipolar disorder ZA963826B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/440,570 US5510381A (en) 1995-05-15 1995-05-15 Method of treatment of mania and bipolar disorder

Publications (1)

Publication Number Publication Date
ZA963826B true ZA963826B (en) 1996-11-21

Family

ID=23749281

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA963826A ZA963826B (en) 1995-05-15 1996-05-14 A method of treatment of mania and bipolar disorder

Country Status (19)

Country Link
US (1) US5510381A (xx)
EP (1) EP0825857B1 (xx)
JP (1) JPH11505244A (xx)
AT (1) ATE218857T1 (xx)
AU (1) AU702435B2 (xx)
CA (1) CA2215923C (xx)
CZ (1) CZ288072B6 (xx)
DE (1) DE69621799T2 (xx)
DK (1) DK0825857T3 (xx)
EE (1) EE03420B1 (xx)
ES (1) ES2177783T3 (xx)
GE (1) GEP20002014B (xx)
HU (1) HUP9802087A3 (xx)
NO (1) NO315967B1 (xx)
NZ (1) NZ307366A (xx)
PT (1) PT825857E (xx)
SK (1) SK281982B6 (xx)
WO (1) WO1996036328A1 (xx)
ZA (1) ZA963826B (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
AU9318398A (en) 1997-10-07 1999-04-27 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
DE69834204T2 (de) * 1997-10-27 2007-03-29 Warner-Lambert Co. Llc Zyklische aminosäuren und deren derivate als arzneimittel
CN100337687C (zh) * 1998-05-15 2007-09-19 沃尼尔·朗伯公司 含有γ－氨基丁酸衍生物的固体组合物及其制备方法
IL139298A0 (en) 1998-05-15 2001-11-25 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
BR9910697A (pt) 1998-05-26 2001-01-30 Warner Lambert Co Compostos aminoácidos comprimidos estruturalmente tendo afinidade à subunidade alfa2delta de um canal de cálcio
PL345338A1 (en) * 1998-07-09 2001-12-17 Warner Lambert Co Method for the treatment of insomnia
DK1121114T3 (da) * 1998-10-16 2007-04-10 Warner Lambert Co Anvendelse af GABA-analoger til fremstilling af et medikament til behandling af mani og bipolære lidelser
WO2000073300A1 (en) * 1999-06-02 2000-12-07 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
CZ200339A3 (cs) * 2000-06-16 2003-06-18 Teva Pharmaceutical Industries Ltd. Stabilní gabapentin vykazující neutrální pH
KR100785182B1 (ko) * 2000-06-26 2007-12-11 워너-램버트 캄파니 엘엘씨 수면 장애를 위한 가바펜틴 유사체
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
IN2012MN02923A (xx) 2010-06-01 2015-06-05 Rubicon Res Private Ltd
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) * 2022-04-13 2023-06-06 Green Sky Creations LLC Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
PT825857E (pt) 2002-11-29
EP0825857A1 (en) 1998-03-04
EP0825857B1 (en) 2002-06-12
GEP20002014B (en) 2000-04-10
DE69621799D1 (de) 2002-07-18
NZ307366A (en) 1999-10-28
AU702435B2 (en) 1999-02-18
CA2215923A1 (en) 1996-11-21
EE03420B1 (et) 2001-06-15
MX9707269A (es) 1997-11-29
NO315967B1 (no) 2003-11-24
NO975234L (no) 1997-11-14
CZ355897A3 (cs) 1998-02-18
US5510381A (en) 1996-04-23
HUP9802087A2 (hu) 1998-12-28
EE9700302A (et) 1998-06-15
SK152897A3 (en) 1999-05-07
JPH11505244A (ja) 1999-05-18
DK0825857T3 (da) 2002-09-30
CA2215923C (en) 2001-10-09
HUP9802087A3 (en) 1999-08-30
NO975234D0 (no) 1997-11-14
AU5668996A (en) 1996-11-29
WO1996036328A1 (en) 1996-11-21
CZ288072B6 (cs) 2001-04-11
ATE218857T1 (de) 2002-06-15
SK281982B6 (sk) 2001-09-11
ES2177783T3 (es) 2002-12-16
DE69621799T2 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
ZA963826B (en) A method of treatment of mania and bipolar disorder
CA2344407A1 (en) Method for the treatment of mania and bipolar disorder
HUS1300046I1 (hu) Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására
CA2258895A1 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
ATE127804T1 (de) Pharmazeutische verbindungen.
AU6256996A (en) Use of vitamin D4 derivatives for treating skin disorders
EP0347864A3 (en) Anti-atherogenic agents
DE69633396D1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
WO1992018536A3 (en) Method for detecting an localizing tissues having neurokinine 1 receptors
WO1998022099A3 (en) New use of creatine
WO1997005864A3 (en) Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs
PL328948A1 (en) Autism treating method
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
ZA963744B (en) Topical aciclovir preparation
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
GB9616549D0 (en) Therapeutic product and its use
MX9801515A (es) Preparado de combinacion para la aplicacion en la demencia.
YU40098A (sh) Upotreba olanzapina za dobijanje leka
SI0825857T1 (en) Use of gabapentin and its derivatives in the treatment of mania and bipolar disorder
IL128768A0 (en) Transdermal therapeutic system containing oestriol
MX9701294A (es) Un medicamento que contiene un derivado de carnitina para el tratamiento de la arterioesclerosis cronica obliteradora.
JO1880B1 (en) Format 1 for multi-unit calibration discs